A phase II study evaluating the utility of letrozole in the treatment of recurrent, estrogen receptor (ER) positive, epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer,

Trial Profile

A phase II study evaluating the utility of letrozole in the treatment of recurrent, estrogen receptor (ER) positive, epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer,

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2006

At a glance

  • Drugs Letrozole (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top